

PatientID: NC640-1997

Okitobba 06, 2023

Color Code

■ HR: High-Level Resistance ■ PLR: Potential Low-Level Resistance
■ LR: Low-Level Resistance ■ IR: Intermediate Resistance
■ S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence
PI	ATV	HR	G48V;I54V;V82A;I84V
	DRV	LR	
	FPV	HR	
	IDV	HR	
	LPV	HR	
	NFV	HR	
	SQV	HR	
	TPV	IR	
NRTI	ABC	IR	L74VL;M41L;T215Y
	AZT	HR	
	D4T	HR	
	DDI	HR	
	FTC	S	
	LMV	S	
	TDF	LR	
NNRTI	DOR	HR	Y181YC;V106AV
	EFV	HR	
	ETR	IR	
	NVP	HR	
	RPV	IR	

Appendix

Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
PI	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
	IDV	Indinavir
	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
NRTI	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
NNRTI	DOR	Doravirine
	EFV	Efavirenz
	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
INSTI	BIC	Bictegravir
	CAB	Cabotegravir
	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

Comments

DRUG.CLASS	COMMENTS
PI	G48V is a nonpolymorphic mutation selected by SQV and less often by IDV and LPV. It confers intermediate resistance to ATV but has little if any effect on LPV susceptibility.
	I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV.
	I84V is a nonpolymorphic substrate-cleft mutation selected by each of the PIs. I84V reduces susceptibility to LPV, ATV, and DRV.
	V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It is associated with reduced susceptibility to LPV and to a lesser extent ATV. It increases DRV susceptibility.
NRTI	L74V causes intermediate ABC resistance. L74I causes low-level ABC resistance.
	M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.
	T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF.
	V106A is a non-polymorphic mutation that confers high-level resistance to NVP and DOR, and intermediate resistance to EFV. It is commonly selected in vitro and in vivo by DOR.

NNRTI	Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. It does not significantly reduce DOR susceptibility.
INSTI	